Improved Clinical Outcomes with the Combination Therapy of a Glucagon-like Peptide-1 Receptor Agonists and a Sodium-glucose Cotransporter-2 Inhibitor in Overweight/Obese People with Type 2 Diabetes: Real-world Evidence from the Indian Subcontinent.
在印度次大陸的超重/肥胖2型糖尿病患者中,使用GLP-1受體激動劑與鈉-葡萄糖共轉運蛋白-2抑制劑聯合療法改善臨床結果的實證研究。
J Assoc Physicians India 2024-09-18
The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function.
抗糖尿病藥物 GLP-1RA 和 SGLT-2i 對呼吸系統功能的可能影響。
Endocrine 2024-09-17
Fibroblast Growth Factor 21 Improves Insulin Sensitivity by Modulating the Bile Acid-Gut Microbiota Axis in Type Ⅱ Diabetic Mice.
Fibroblast Growth Factor 21 透過調節膽汁酸-腸道微生物群軸改善 II 型糖尿病小鼠的胰島素敏感性。
Free Radic Biol Med 2024-09-17
Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.
GLP-1 受體激動劑在物質使用障礙中的潛在角色:隨機試驗的系統性回顧。
Drug Alcohol Depend 2024-09-17
The Definition and Prevalence of Obesity and Metabolic Syndrome: Correlative Clinical Evaluation Based on Phenotypes.
肥胖和代謝綜合症的定義與流行病學:基於表現型的相關臨床評估。
Adv Exp Med Biol 2024-09-17
Lipopolysaccharide accelerates peristalsis by stimulating glucagon-like peptide-1 release from L cells in the rat proximal colon.
脂多醣通過刺激大鼠近端結腸 L 細胞釋放胰高血糖素樣肽-1 來加速蠕動。
J Physiol 2024-09-17